Metropolis Healthcare Limited Stock Price Today (NSE: METROPOLIS)
Metropolis Healthcare Limited
Fundamental Score
Metropolis Healthcare Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Metropolis Healthcare Limited share price today is ₹566.70, up +2.67% on NSE/BSE as of 25 August 2026. Metropolis Healthcare Limited (METROPOLIS) is a Mid-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹11.86K (Cr). The 52-week high for METROPOLIS share price is ₹2263.00 and the 52-week low is ₹412.25. At a P/E ratio of 58.81x, METROPOLIS is currently trading above its industry average P/E of 42.23x. The company has a Return on Equity (ROE) of 13.36% and a debt-to-equity ratio of 0.01.
Metropolis Healthcare Limited Share Price Chart — NSE/BSE Historical Performance
Metropolis Healthcare Limited share price chart: -1.84% return over the past month. 52-week high ₹2263.00, 52-week low ₹412.25.
Metropolis Healthcare Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹566.95 | ₹569.00 | ₹563.00 | ₹566.70 | 1.51L (Cr) | |
| ₹553.00 | ₹555.75 | ₹545.20 | ₹551.95 | 1.19L (Cr) | |
| ₹560.00 | ₹561.00 | ₹542.20 | ₹545.50 | 2.42L (Cr) | |
| ₹555.00 | ₹560.90 | ₹550.05 | ₹558.50 | 1.77L (Cr) | |
| ₹570.00 | ₹582.40 | ₹550.10 | ₹552.40 | 3.65L (Cr) | |
| ₹577.00 | ₹577.00 | ₹562.35 | ₹566.25 | 2.02L (Cr) | |
| ₹565.00 | ₹574.90 | ₹559.30 | ₹572.65 | 1.43L (Cr) | |
| ₹560.00 | ₹572.60 | ₹559.25 | ₹563.20 | 1.32L (Cr) | |
| ₹582.35 | ₹588.65 | ₹551.10 | ₹564.60 | 2.18L (Cr) | |
| ₹590.00 | ₹592.00 | ₹571.30 | ₹576.75 | 2.37L (Cr) |
Metropolis Healthcare Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹584.95 | ₹605.00 | ₹542.20 | ₹566.70 | -3.12% | |
| ₹540.15 | ₹609.05 | ₹532.00 | ₹582.45 | +7.83% | |
| ₹560.00 | ₹563.50 | ₹515.00 | ₹540.15 | -3.54% | |
| ₹472.20 | ₹600.00 | ₹472.20 | ₹555.35 | +17.61% | |
| ₹444.00 | ₹494.40 | ₹412.25 | ₹476.50 | +7.32% | |
| ₹460.25 | ₹478.50 | ₹414.20 | ₹434.00 | -5.70% | |
| ₹1904.80 | ₹2044.00 | ₹463.40 | ₹475.95 | -75.01% | |
| ₹1935.00 | ₹2060.00 | ₹1745.10 | ₹1873.00 | -3.20% | |
| ₹1930.30 | ₹1969.10 | ₹1836.10 | ₹1928.90 | -0.07% | |
| ₹1980.60 | ₹2118.30 | ₹1914.20 | ₹1931.00 | -2.50% | |
| ₹2033.20 | ₹2160.00 | ₹1887.20 | ₹1970.40 | -3.09% | |
| ₹2200.00 | ₹2263.00 | ₹1915.90 | ₹2036.00 | -7.45% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Metropolis is an overvalued roll-up story in a commoditized market; avoid until the P/E comes back to earth.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Metropolis Healthcare allotted 15,54,95,826 bonus shares in a 3:1 ratio on March 23, 2026. Q3FY26 results showed a 26% YoY revenue increase to , with net profit jumping 63% YoY to However, recent quarterly results show a QoQ decrease in revenue, operating profit, PBDT, profit before tax and net profit.
CORE STORY (THE REAL GAME)
Metropolis is being priced as a growth story in the Indian diagnostics sector, fueled by acquisitions and expansion into Tier II and Tier III cities. The market is betting on Metropolis consolidating its position through inorganic growth and increasing its advanced diagnostics offerings.
- Q3FY26 revenue growth of 26% YoY
- Successful bonus share allotment
- Expansion into Tier II and Tier III cities
- Successful integration of recent acquisitions
- Further expansion into underserved markets
- Increased adoption of advanced diagnostics
- Expensive valuation (P/E 63.98x vs industry 39.28x)
- Negative profit CAGR 5Y (-0.56%)
- Reliance on acquisitions for growth
FII decreased holdings by 0.31%, while DII increased holdings by 0.7% [cite: brief]. Mixed signals.
Increasing healthcare spending and awareness in India are tailwinds, but competition is fierce.
Profit converting to cash (Free Cash Flow 5Y: ₹1034.52 Cr)
Expect moderate growth in the next 3-6 months driven by organic expansion and recent acquisitions. Key is successful integration and realization of synergies.
Primary Thesis Risk
Overpaying for acquisitions and failing to integrate them will destroy shareholder value.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Metropolis Healthcare Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Metropolis Healthcare Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of METROPOLIS across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Excellent ROCE Performance (16.80%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (25.67%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (25.76%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (16.62%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (11.56x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1118.72 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 46.23%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 58.81x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (7.84x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-23.88% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (0.74% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Metropolis Healthcare Limited vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare Metropolis Healthcare Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Metropolis Healthcare LimitedMetropolis Heal...Selected✓ METROPOLIS • 542650 | 57.9/100 | ₹566.70₹567 | ₹11858.49₹11858.49 | 58.81Average 58.8 Average | 13.36%Average 13.36% Average | 16.80%Good 16.80% Good | 0.01Excellent 0.0 Excellent | 0.74%Average 0.74% Average | 10.52%Good 10.52% Good | 0.35% |
Dr. Lal Path Labs Ltd.Dr. Lal Path La... LALPATHLAB • 539524 | 57.7/100 | ₹1913.70₹1914 | ₹28908.91₹28908.91 | 53.35Average 53.3 Average | 21.57%Excellent 21.57% Excellent | 27.62%Excellent 27.62% Excellent | 0.00Excellent 0.0 Excellent | 11.60%Good 11.60% Good | 11.81%Good 11.81% Good | 0.81% |
Vijaya Diagnostic Centre LimitedVijaya Diagnost... VIJAYA • 543350 | 67.8/100 | ₹1483.40₹1483 | ₹14307.85₹14307.85 | 76.31Average 76.3 Average | 19.74%Good 19.74% Good | 21.32%Excellent 21.32% Excellent | 0.00Excellent 0.0 Excellent | — — | — — | 0.14% |
Thyrocare Technologies LimitedThyrocare Techn... THYROCARE • 539871 | 46.7/100 | ₹596.05₹596 | ₹8420.27₹8420.27 | 47.76Average 47.8 Average | 28.80%Excellent 28.80% Excellent | 35.47%Excellent 35.47% Excellent | 0.00Excellent 0.0 Excellent | — — | 10.88%Good 10.88% Good | 1.76% |
Krsnaa Diagnostics LimitedKrsnaa Diagnost... KRSNAA • 543328 | 31.9/100 | ₹564.80₹565 | ₹1777.47₹1777.47 | 21.62Average 21.6 Average | 10.89%Average 10.89% Average | 13.05%Average 13.05% Average | 0.55Good 0.5 Good | — — | — — | 0.50% |
Suraksha Diagnostic LimitedSuraksha Diagno... SURAKSHA • 544293 | 56.2/100 | ₹317.85₹318 | ₹1359.30₹1359.30 | 37.97Average 38.0 Average | 14.11%Average 14.11% Average | 16.82%Good 16.82% Good | 0.01Excellent 0.0 Excellent | — — | — — | 0.00% |
One Global Service Provider LimitedOne Global Serv... ONEGLOBAL • 514330 | 82.2/100 | ₹546.20₹546 | ₹1178.25₹1178.25 | — — | — — | — — | — — | — — | — — | 0.00% |
3B Blackbio Dx Limited3B Blackbio Dx ... 3BBLACKBIO • 532067 | 60.3/100 | ₹1262.40₹1262 | ₹1079.13₹1079.13 | — — | — — | — — | — — | — — | — — | 0.31% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 39/100 | ₹301.45₹301 | ₹1035.54₹1035.54 | 539.34Average 539.3 Average | 0.29%Poor 0.29% Poor | -0.05%Poor -0.05% Poor | 0.04Excellent 0.0 Excellent | 16.91%Excellent 16.91% Excellent | 19.09%Excellent 19.09% Excellent | 0.00% |
49.4/100 | ₹220.15₹220 | ₹600.78₹600.78 | 20.55Average 20.6 Average | 19.92%Good 19.92% Good | 23.27%Excellent 23.27% Excellent | 0.31Excellent 0.3 Excellent | — — | — — | 0.00% | |
Aspira Pathlab & Diagnostics LimitedAspira Pathlab ... ASPIRA • 540788 | 11.9/100 | ₹93.70₹94 | ₹88.52₹88.52 | 1770.34Average 1770.3 Average | 0.51%Poor 0.51% Poor | 2.84%Poor 2.84% Poor | 0.27Excellent 0.3 Excellent | -48.50%Poor -48.50% Poor | 10.43%Good 10.43% Good | 0.00% |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Dr. Lal Path Labs Ltd. share price28908.91 Cr
- Vijaya Diagnostic Centre Limited share price14307.85 Cr
- Thyrocare Technologies Limited share price8420.27 Cr
- Krsnaa Diagnostics Limited share price1777.47 Cr
- Suraksha Diagnostic Limited share price1359.30 Cr
Metropolis Healthcare Limited PE Ratio History
Historical price-to-earnings ratio for METROPOLIS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹28.15 | ₹1928.90 | 68.5x |
| FY 2024 | ₹24.87 | ₹2076.65 | 83.5x |
| FY 2023 | ₹27.81 | ₹1678.15 | 60.3x |
| FY 2022 | ₹41.66 | ₹1327.50 | 31.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Metropolis Healthcare Limited Dividend History
Annual cash dividends paid by METROPOLIS — dividend yield 0.35%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹20.50 Cr |
| FY 2023 | ₹40.97 Cr |
| FY 2022 | ₹40.94 Cr |
| FY 2021 | ₹40.89 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Metropolis Healthcare Limited Quarterly Performance
Latest quarterly metrics for METROPOLIS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
16.62%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
25.76%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.52%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
0.74%
Compounded annual net profit growth over 5 years
Metropolis Healthcare Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for METROPOLIS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Metropolis Healthcare Limited Financial Statements
Annual income statement, balance sheet and cash flow for Metropolis Healthcare Limited (METROPOLIS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Metropolis Healthcare Limited
About METROPOLIS (Metropolis Healthcare Limited)
Metropolis Healthcare Ltd is a leading diagnostics company renowned for its comprehensive suite of services, extending from routine pathology tests to cutting-edge advanced diagnos...tics. With a legacy spanning decades, Metropolis has established itself as a trusted healthcare partner, committed to delivering accurate and reliable results that empower informed clinical decisions. Beyond standard blood tests and analyses, the company excels in specialised areas such as genetic testing, molecular diagnostics, and cytogenetic evaluations, catering to a wide spectrum of medical needs. Metropolis also prioritises preventive healthcare through tailored wellness packages and corporate screening programs, aimed at early detection and proactive health management. The breadth and depth of their offerings underscore Metropolis' dedication to holistic patient care and diagnostic excellence. Central to Metropolis' operational strength is its commitment to innovation and technological advancement. The company continuously invests in state-of-the-art laboratory equipment and employs rigorous quality control measures to ensure the highest standards of accuracy and efficiency. Furthermore, Metropolis offers convenient home collection services, bringing diagnostic care directly to patients' doorsteps, thereby enhancing accessibility and convenience. The organisation understands the importance of accurate and timely results so they contribute to improved patient outcomes. Metropolis also contributes to groundbreaking medical research by supporting clinical trials, leveraging its expertise in laboratory services. This focus on research not only advances scientific knowledge but also positions Metropolis at the forefront of diagnostic innovation. Metropolis Healthcare Ltd's influence extends beyond domestic borders, with a significant presence in international markets, including Africa, South Asia, and the Middle East. This global footprint reflects the company's commitment to providing quality diagnostic services to diverse populations and contributing to improved healthcare outcomes worldwide. Through its network of laboratories and collection centres, Metropolis delivers comprehensive diagnostic solutions to healthcare providers, hospitals, and individual patients. Moreover, the company's expertise in hospital lab management ensures efficient and effective laboratory operations within healthcare facilities, further enhancing the quality of patient care. By embracing innovation, maintaining uncompromising quality standards, and expanding its reach, Metropolis continues to shape the future of diagnostics and improve healthcare outcomes globally.
Company Details
Key Leadership
Corporate Events
METROPOLIS Share Price: Frequently Asked Questions
What is the current share price of Metropolis Healthcare Limited?
Metropolis Healthcare Limited (METROPOLIS) trades at ₹566.70 on NSE and BSE. Market cap ₹11.86K (Cr). Educational data only.
What is the P/E ratio of Metropolis Healthcare Limited?
Metropolis Healthcare Limited has a P/E of 58.81x vs industry average 42.23x.
What is the Bull Run score for Metropolis Healthcare Limited?
Metropolis Healthcare Limited has a Bull Run score of 57.9/100 based on 25+ financial parameters.
Does Metropolis Healthcare Limited pay dividends?
Metropolis Healthcare Limited has a dividend yield of 0.35%. Past dividends don't guarantee future payments.
What is the ROE of Metropolis Healthcare Limited?
Metropolis Healthcare Limited has ROE of 13.36%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Metropolis Healthcare Limited?
Metropolis Healthcare Limited has debt-to-equity of 0.01.
Is Metropolis Healthcare Limited a good investment?
Bull Run gives Metropolis Healthcare Limited a score of 57.9/100. This is not investment advice — consult a SEBI-registered advisor.